Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatme...(n the overall rate was 33percent lower t...),Health

Date:10/22/2007

n the overall rate was 33 percent lower than the orlistat 120mg group. In fact, researchers determined that when alli was used for three months without physician supervision in a non-controlled setting, the overall incidence of treatment effects was 20 percent lower compared to controlled studies. These data support the proposition that most patients can successfully modify their eating habits to comply with the alli plan.

"The alli data we're reviewing show that treatment effects are not a major issue for most patients taking alli because they are highly motivated by the weight loss achieved. In addition, many alli users have repeatedly told us that they view treatment effects as a positive tool to help make them aware of hidden fats in foods. Thus, alli capsules, in addition to the alli program, provides patients with a powerful tool that they can use to achieve their weight loss goals and embrace healthier lifestyle behaviors," commented Vidhu Bansal-Dev, PharmD, director, Medical Affairs, GlaxoSmithKline Consumer Healthcare.

Consumer Feedback

In addition to the cumulative data analysis released at NAASO, recently collected consumer data show overall satisfaction with the alli weight loss program was ranked at 85 percent among alli First Team members. Moreover, a new consumer survey conducted by Nielsen and funded by GlaxoSmithKline Consumer Healthcare showed nearly 70 percent of people reported losing weight after starting the alli program.

About Overweight and Obesity

Currently, approximately 65 percent of U.S. adults are overweight or obese, according to the National Institutes of Health. Research suggests that overweight individuals appear to be on the pathway to obesity. Overweight and obesity are associated with an increased risk of developing health problems such as hypertension, type 2 diabetes and heart disease. Factors that can contribute to overweight include an abundance of high-calorie foods, low levels of physical activ
'/>"/>

SOURCE GlaxoSmithKline Consumer Healthcare Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea